期刊
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
卷 68, 期 5, 页码 427-430出版社
INFORMA HEALTHCARE
DOI: 10.1080/00365510701810621
关键词
anticoagulation; pharmacogenetics; polymorphism; vitamin K epoxide reductase; warfarin
资金
- Ostergotland and the Medical Research Council of Southeast Sweden (FORSS)
Vitamin K epoxide reductase complex subunit 1 (VKORC1) is the site of inhibition by warfarin and other antivitamin K drugs during oral anticoagulant therapy. The SNP rs9934438 in intron 1 of VKORC1 (c.173+1000C > T or 1173C > T) discriminating the VKORC1*2 haplotype is associated with low warfarin dose requirement and unstable prothrombin time - international normalized ratio. To genotype this SNP, we have developed a rapid method using Pyrosequencing (R) technology. The proposed method takes a post-PCR sample preparation of less than 1 h and a DNA sequencing time of less than 15 min to genotype 96 samples. The current method was compared with a dHPLC method that we reported previously. Genotype frequencies at VKORC1 1173C > T for our Swedish population were 38 % wild-type, 40 % heterozygote and 22 % homozygote. The frequency of the T-allele was 0.42, which exactly matches the frequency previously reported for Germans. The current method can be used to determine whether patients initiating warfarin therapy are carriers of SNP 1173 C > T that is strongly associated with low warfarin dose requirement.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据